Hulihan, Joseph (2001). «IMPORTANT DRUG WARNING»(PDF). FDA MedWatch. Ortho-McNeil Pharmaceutical. Αρχειοθετήθηκε από το πρωτότυπο(PDF) στις 13 Ιανουαρίου 2017. Ανακτήθηκε στις 11 Ιουνίου 2018.
Ferrari, A; Tiraferri, I; Neri, L; Sternieri, E (September 2011). «Clinical pharmacology of topiramate in migraine prevention.». Expert Opinion on Drug Metabolism & Toxicology7 (9): 1169–81. doi:10.1517/17425255.2011.602067. PMID21756204.
Evers, S.; Jensen, R. (September 2011). «Treatment of medication overuse headache - guideline of the EFNS headache panel». European Journal of Neurology18 (9): 1115–1121. doi:10.1111/j.1468-1331.2011.03497.x. PMID21834901.
Kramer, CK; Leitão, CB; Pinto, LC; Canani, LH; Azevedo, MJ; Gross, JL (May 2011). «Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials.». Obesity Reviews12 (5): e338–47. doi:10.1111/j.1467-789X.2010.00846.x. PMID21438989.
Hahn, MK; Cohn, T; Teo, C; Remington, G (January 2013). «Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.». Clinical Schizophrenia & Related Psychoses6 (4): 186–96. doi:10.3371/CSRP.HACO.01062013. PMID23302448.
Mahmood, S; Booker, I; Huang, J; Coleman, CI (February 2013). «Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents.». Journal of Clinical Psychopharmacology33 (1): 90–4. doi:10.1097/JCP.0b013e31827cb2b7. PMID23277264.
Wills (2014), «Clinical Outcomes in Newer Anticonvulsant Overdose: A Poison Center Observational Study», J. Med. Toxicol.10 (3): 254–260, doi:10.1007/s13181-014-0384-5, PMID24515527
Lofton, AL; Klein-Schwartz, W (2005), «Evaluation of toxicity of topiramate exposures reported to poison centers», Human & Experimental Toxicology24 (11): 591–595, doi:10.1191/0960327105ht561oa, PMID16323576
Kudin, AP; Debska-Vielhaber, G; Vielhaber, S; Elger, CE; Kunz, WS (2004). «The mechanism of neuroprotection by topiramate in an animal model of epilepsy». Epilepsia45 (12): 1478–87. doi:10.1111/j.0013-9580.2004.13504.x. PMID15571505.
Hulihan, Joseph (2001). «IMPORTANT DRUG WARNING»(PDF). FDA MedWatch. Ortho-McNeil Pharmaceutical. Αρχειοθετήθηκε από το πρωτότυπο(PDF) στις 13 Ιανουαρίου 2017. Ανακτήθηκε στις 11 Ιουνίου 2018.
Ferrari, A; Tiraferri, I; Neri, L; Sternieri, E (September 2011). «Clinical pharmacology of topiramate in migraine prevention.». Expert Opinion on Drug Metabolism & Toxicology7 (9): 1169–81. doi:10.1517/17425255.2011.602067. PMID21756204.
Evers, S.; Jensen, R. (September 2011). «Treatment of medication overuse headache - guideline of the EFNS headache panel». European Journal of Neurology18 (9): 1115–1121. doi:10.1111/j.1468-1331.2011.03497.x. PMID21834901.
Kramer, CK; Leitão, CB; Pinto, LC; Canani, LH; Azevedo, MJ; Gross, JL (May 2011). «Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials.». Obesity Reviews12 (5): e338–47. doi:10.1111/j.1467-789X.2010.00846.x. PMID21438989.
Hahn, MK; Cohn, T; Teo, C; Remington, G (January 2013). «Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.». Clinical Schizophrenia & Related Psychoses6 (4): 186–96. doi:10.3371/CSRP.HACO.01062013. PMID23302448.
Mahmood, S; Booker, I; Huang, J; Coleman, CI (February 2013). «Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents.». Journal of Clinical Psychopharmacology33 (1): 90–4. doi:10.1097/JCP.0b013e31827cb2b7. PMID23277264.
Wills (2014), «Clinical Outcomes in Newer Anticonvulsant Overdose: A Poison Center Observational Study», J. Med. Toxicol.10 (3): 254–260, doi:10.1007/s13181-014-0384-5, PMID24515527
Lofton, AL; Klein-Schwartz, W (2005), «Evaluation of toxicity of topiramate exposures reported to poison centers», Human & Experimental Toxicology24 (11): 591–595, doi:10.1191/0960327105ht561oa, PMID16323576
Kudin, AP; Debska-Vielhaber, G; Vielhaber, S; Elger, CE; Kunz, WS (2004). «The mechanism of neuroprotection by topiramate in an animal model of epilepsy». Epilepsia45 (12): 1478–87. doi:10.1111/j.0013-9580.2004.13504.x. PMID15571505.